Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab

被引：6

作者：

Camelo, Ricardo Mesquita ^{[1
,2
]}

Barbosa, Mariana Michel ^{[3
]}

Araujo, Maiara Silva ^{[3
]}

Muniz, Roberto Lucio, Jr. ^{[3
]}

Guerra, Augusto Afonso, Jr. ^{[3
]}

Godman, Brian ^{[4
,5
,6
]}

Rezende, Suely Meireles ^{[1
]}

Acurcio, Francisco de Assis ^{[3
]}

Martin, Antony P. ^{[7
,8
]}

Alvares-Teodoro, Juliana ^{[3
]}

机构：

[1] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil

[2] Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands

[3] Univ Fed Minas Gerais, Fac Pharm, Belo Horizonte, MG, Brazil

[4] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland

[5] Ajman Univ, Ctr Med & Bioallied Hlth Sci Res, Ajman, U Arab Emirates

[6] Sefako Makgatho Hlth Sci Univ, Sch Pharm, Pretoria, South Africa

[7] Fac Hlth & Life Sci, Liverpool, Merseyside, England

[8] QC Med, York, N Yorkshire, England

来源：

VALUE IN HEALTH REGIONAL ISSUES | 2023年 / 34卷

关键词：

activated prothrombin complex concentrate; bypassing agents; cost-effectiveness analysis; emicizumab; immune tolerance induction; prophylaxis; recombinant activated factor VII; BYPASSING AGENTS; GUIDELINES; MANAGEMENT; FEIBA;

D O I：

10.1016/j.vhri.2022.10.007

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Objective: This study aimed to measure the cost-effectiveness of prophylaxis with emicizumab in PsHAhri on ITI in Brazil. Methods: A cost-effectiveness modeling analysis was used to estimate the costs per PsHAhri on ITI and the number of prevented bleedings from undertaking one intervention (prophylaxis with BpA) over another (prophylaxis with emicizumab), based on the Brazilian Ministry of Health perspective. Costs of ITI with recombinant FVIII, prophylaxis with BpA or emicizumab, and treated bleeding episodes with BpA costs were evaluated for PsHAhri who had ITI success or failure. This study was conducted with the perspective of the Brazilian Ministry of Health (payer). Results: During ITI, prophylaxis with BpA cost US $924 666/PsHAhri/ITI, whereas prophylaxis with emicizumab cost US $488 785/PsHAhri/ITI. During ITI, there was an average of 9.32 bleeding episodes/ PsHAhri/ITI when BpA were used as prophylaxis and 0.67 bleeding/PsHAhri/ITI when emicizumab was used. By univariate deterministic sensitivity analysis, emicizumab remained dominant whichever variable was modified. Conclusion: In this study, prophylaxis with emicizumab during ITI is a dominant option compared with prophylaxis with BpA during ITI.

引用

页码：31 / 39

页数：9

共 47 条

[1] Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy [J].

Abbonizio, F. ;

Giampaolo, A. ;

Coppola, A. ;

Arcieri, R. ;

Hassan, H. J. .

HAEMOPHILIA, 2014, 20 (04) :e243-e250

[2]

[Anonymous], HEIGHT WEIGHT MEDIAN

[3]

[Anonymous], IM PROT US IND IM PA

[4] A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study [J].

Astermark, Jan ;

Donfield, Sharyne M. ;

DiMichele, Donna M. ;

Gringeri, Alessandro ;

Gilbert, Steven A. ;

Waters, Jennifer ;

Berntorp, Erik .

BLOOD, 2007, 109 (02) :546-551

[5] Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis [J].

Batsuli, Glaivy ;

Zimowski, Karen L. ;

Tickle, Kelly ;

Meeks, Shannon L. ;

Sidonio, Robert F., Jr. .

HAEMOPHILIA, 2019, 25 (05) :789-796

[6] Emicizumab: A Review in Haemophilia A [J].

Blair, Hannah A. .

DRUGS, 2019, 79 (15) :1697-1707

[7]

Brasil. Ministerio da Saude, MAN HEM

[8] The societal burden of haemophilia A. III - The potential impact of emicizumab on costs of haemophilia A in Australia [J].

Brown, Laurie J. ;

La, Hai A. ;

Li, Jinjing ;

Brunner, Matthias ;

Snoke, Martin ;

Kerr, Annette M. .

HAEMOPHILIA, 2020, 26 :21-29

[9] Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors [J].

Bykov, Katsiaryna ;

Bohn, Rhonda L. ;

Ewenstein, Bruce M. ;

Seeger, John D. ;

Avorn, Jerry ;

Bateman, Brian T. .

THROMBOSIS AND HAEMOSTASIS, 2017, 117 (12) :2267-2273

[10] Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies [J].

Callaghan, Michael U. ;

Negrier, Claude ;

Paz-Priel, Ido ;

Chang, Tiffany ;

Chebon, Sammy ;

Lehle, Michaela ;

Mahlangu, Johnny ;

Young, Guy ;

Kruse-Jarres, Rebecca ;

Mancuso, Maria Elisa ;

Niggli, Markus ;

Howard, Monet ;

Bienz, Nives Selak ;

Shima, Midori ;

Jimenez-Yuste, Victor ;

Schmitt, Christophe ;

Asikanius, Elina ;

Levy, Gallia G. ;

Pipe, Steven W. ;

Oldenburg, Johannes .

BLOOD, 2021, 137 (16) :2231-2242

← 1 2 3 4 5 →